Bli medlem
Bli medlem

Du är här


Immunicum AB: Immunicum AB presented poster at SITC conference on INTUVAX HCC I/II clinical study - announces last patient included in study extension

GOTHENBURG, Sweden, November 14, 2016 -
Immunicum AB (publ; First North Premier: IMMU.ST)
, a biopharmaceutical company striving to develop sophisticated, safe and
efficacious therapeutic cancer treatments inducing powerful and long lasting
immune responses, today announced updated immunological and survival phase
I/II data on hepatocellular carcinoma (HCC) patients treated with INTUVAX.

The results were presented in a poster session by Immunicum's Chief Scientific
Officer, Alex Karlsson-Parra, on November 12th, 2016 at the Society for
Immunotherapy of Cancer (SITC) 31stAnnual Meeting, held in National Harbor,

"The clinical data presented at the SITC annual meeting, in addition to our
previous announcements about the trial, provide important information that we
intend to use as a basis for developing INTUVAX to be an effective
immuno-oncological treatment for a range of cancers. We have extended the
study with six additional patients that received INTUVAX as first line
systemic treatment in combination with standard treatments, which will allow
us to better measure the impact of the approach", said Dr. Carlos de Sousa,
CEO of Immunicum.

"Also, I can now announce that the last patient has been included in the study
extension. In the upcoming Q1 report we will provide a general company update
including clinical activities", he added.

The poster - titled "Intratumorally injected pro-inflammatory allogeneic
dendritic cells as immune enhancers - a phase I/II study in patients with
advanced hepatocellular carcinoma" - showed that 67% of fully treated
patients with advanced HCC experienced increases in circulating
tumor-specific CD8+ T cells.

Moreover, these increases appear to correlate with prolonged survival rates
seen in the study as compared to historical median overall survival rates as
documented in medical literature. In addition, these results support the
achievement of the primary endpoint of the study since INTUVAX demonstrated a
positive safety and tolerability profile with only two patients exhibiting
treatment related serious adverse events (specifically fever which can be
interpreted as a sign of systemic immune responsiveness towards the injected
INTUVAX cells).

The full poster is available as a .pdf file on the Immunicum website under the
following link:

About the phase I/II study in HCC

In late 2013, Immunicum initiated a clinical phase I/II study with its lead
cancer immune primer, INTUVAX, as second line treatment in eleven patients
with advanced hepatocellular carcinoma that had previously failed on first
line standard treatments. Patients were treated with three intratumoral doses
of INTUVAX as monotherapy with the primary objective to determine safety, and
secondary objectives to determine immunological response and efficacy.

For more information, please contact

Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52


INTUVAX is a cancer immune primer, developed for the treatment of solid
tumors. Its active ingredient is activated white blood cells, so called
dendritic cells, derived from healthy blood donors. Intratumoral injection of
these cells is expected to lead to an inflammatory response which in turn
leads to tumor-specific activation of the patient's cytotoxic T lymphocytes.

About Immunicum AB (publ)

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor
diseases. A phase II clinical trial for the company's most advanced product -
INTUVAX®against kidney cancer - has been initiated. The project portfolio
contains additional clinical phase I/II studies in liver cancer and in

gastrointestinal stromal tumors (GIST). Immunicum is listed on First North

The company's Certified Adviser is Redeye AB
Ph: + 46 8 545 013 31

The information in this press release is disclosed pursuant to the EU Market
Abuse Regulation. The information was released for public disclosure through
the agency of the company's contact person on November 14, 2016 at 08.45 CET.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.